Atrium Therapeutics, Inc. (RNA)
$8.40+1.69%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $144M
- Beta
- 0.37
- P/E (TTM)
- -2.08
- Short % float
- 21.60%
- Days to cover
- 8.3
- SI change
- -0.1%
- 1W
- +7.14%
- 1M
- -18.84%
- vs SPY 1W
- +5.98%
- vs SPY 1M
- -21.83%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RNA?
- LOPJLB’s latest quantitative signal on Atrium Therapeutics, Inc. (RNA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RNA in?
- Atrium Therapeutics, Inc. (RNA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Atrium Therapeutics, Inc. (RNA) do?
- Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at…